405 related articles for article (PubMed ID: 27337847)
1. [HYPERURICEMIA AND POTENTIAL RISK OF CARDIOVASCULAR AND RENAL DISEASES].
Schils R; Krzesinski JM
Rev Med Liege; 2016 May; 71(5):262-8. PubMed ID: 27337847
[TBL] [Abstract][Full Text] [Related]
2. Update on gout and hyperuricemia.
Baker JF; Schumacher HR
Int J Clin Pract; 2010 Feb; 64(3):371-7. PubMed ID: 19909378
[TBL] [Abstract][Full Text] [Related]
3. [Gout and cardiovascular risk].
Němec P
Vnitr Lek; 2014 Oct; 60(10):893-901. PubMed ID: 25382012
[TBL] [Abstract][Full Text] [Related]
4. [Other antihyperuricemic agents].
Ogino K; Igawa O; Hisatome I
Nihon Rinsho; 2008 Apr; 66(4):754-7. PubMed ID: 18409527
[TBL] [Abstract][Full Text] [Related]
5. The role of urate-lowering treatment on cardiovascular and renal disease: evidence from CARES, FAST, ALL-HEART, and FEATHER studies.
Pontremoli R
Curr Med Res Opin; 2017 Nov; 33(sup3):27-32. PubMed ID: 28952388
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat--treatment for hyperuricemia and gout?
Moreland LW
N Engl J Med; 2005 Dec; 353(23):2505-7. PubMed ID: 16339099
[No Abstract] [Full Text] [Related]
7. A new standard of care? Studies on febuxostat in the management of hyperuricemia with and without gout.
Kamatani N; Hosoya T
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S11-2. PubMed ID: 21654264
[No Abstract] [Full Text] [Related]
8. Effects of xanthine oxidase inhibitors on cardiovascular disease in patients with gout: a cohort study.
Kim SC; Schneeweiss S; Choudhry N; Liu J; Glynn RJ; Solomon DH
Am J Med; 2015 Jun; 128(6):653.e7-653.e16. PubMed ID: 25660249
[TBL] [Abstract][Full Text] [Related]
9. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
10. Cardiovascular and renal effects of hyperuricaemia and gout.
Viazzi F; Leoncini G; Pontremoli R
Reumatismo; 2012 Jan; 63(4):253-62. PubMed ID: 22303532
[TBL] [Abstract][Full Text] [Related]
11. [Hyperuricemia, gout and high cardiovascular risk - how to manage them in clinical practice].
Fomin VV; Morosova TE; Tsurko VV
Ter Arkh; 2019 Dec; 91(12):75-83. PubMed ID: 32598593
[TBL] [Abstract][Full Text] [Related]
12. Treating hyperuricemia of gout: safety and efficacy of febuxostat and allopurinol in older versus younger subjects.
Becker MA; MacDonald PA; Hunt B; Gunawardhana L
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1011-7. PubMed ID: 22132950
[TBL] [Abstract][Full Text] [Related]
13. The problem of cardio-renal diseases in patients with gout.
Ferri C
Curr Med Res Opin; 2017 Nov; 33(sup3):9-13. PubMed ID: 28952391
[TBL] [Abstract][Full Text] [Related]
14. Uric acid lowering therapy in cardiovascular diseases.
Volterrani M; Iellamo F; Sposato B; Romeo F
Int J Cardiol; 2016 Jun; 213():20-2. PubMed ID: 26386814
[TBL] [Abstract][Full Text] [Related]
15. Gout: a clinical syndrome illustrated and discussed.
Bhansing KJ; van Bon L; Janssen M; Radstake TR
Neth J Med; 2010 Sep; 68(9):352-9. PubMed ID: 20876915
[TBL] [Abstract][Full Text] [Related]
16. Clinical practice. Gout.
Neogi T
N Engl J Med; 2011 Feb; 364(5):443-52. PubMed ID: 21288096
[No Abstract] [Full Text] [Related]
17. Improving cardiovascular and renal outcomes in gout: what should we target?
Richette P; Perez-Ruiz F; Doherty M; Jansen TL; Nuki G; Pascual E; Punzi L; So AK; Bardin T
Nat Rev Rheumatol; 2014 Nov; 10(11):654-61. PubMed ID: 25136785
[TBL] [Abstract][Full Text] [Related]
18. Confessions of a goutophile: Despite its treatability, gout remains a problem.
Mandell BF
Cleve Clin J Med; 2008 Jul; 75 Suppl 5():S1. PubMed ID: 18819328
[No Abstract] [Full Text] [Related]
19. Medical implications of hyperuricemia.
Sachs L; Batra KL; Zimmermann B
Med Health R I; 2009 Nov; 92(11):353-5. PubMed ID: 19999892
[No Abstract] [Full Text] [Related]
20. Placebo-controlled double-blind dose-response study of the non-purine-selective xanthine oxidase inhibitor febuxostat (TMX-67) in patients with hyperuricemia (including gout patients) in japan: late phase 2 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S35-43. PubMed ID: 21654268
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
